PBOC Supports Banks' Moderate Bond Buying, Flags Excessive Risk
China's central bank is encouraging smaller lenders to invest in sovereign bonds 'within reasonable limits,' while continuing to caution against excessive risk-taking.
Medium-to-small banks should balance returns with risk management in their bond investments, Cao Yuanyuan, director of the People's Bank of China 's Financial Market Department, said at a press briefing on Monday. Financial institutions with aggressive bond portfolios should remain vigilant about interest rates and credit risks, Cao said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
VeriSign (VRSN) Announced Increased Earnings
In July 2025, VeriSign expanded its buyback authorization and announced increased earnings, alongside a declared cash dividend. Despite these positive developments, the company's share price declined by 5.90% over the past month. This decline coincided with a broader market downturn, driven by global tariff uncertainties and disappointing job data. While VeriSign's solid financial results might have typically buoyed investor confidence, the market context placed downward pressure on its stock. The company's follow-on equity offering also added complexity to its share dynamics over this period, contributing to a challenging market performance. Every company has risks, and we've spotted 3 warning signs for VeriSign (of which 1 shouldn't be ignored!) you should know about. Rare earth metals are the new gold rush. Find out which 25 stocks are leading the charge. VeriSign's recent expansion of its buyback authorization and earnings increase, juxtaposed with a share price decline of 5.90% during July, showcases the complexity of market dynamics. This decline coincided with external market pressures like global tariff uncertainties and disappointing job data. Despite these pressures, VeriSign's solid financial results and strategic initiatives may support long-term growth. Notably, in the last year, VeriSign's total return, including dividends, was 41.76%, highlighting its strong performance over a broader timeline despite recent challenges. Comparatively, over the past year, VeriSign outperformed the US market, which returned 16.8%, and also exceeded the US IT industry with its 24.5% return. The company's ongoing initiatives, such as improving domain registration trends and marketing strategies, could positively impact revenue growth, while the introduction of dividends reflects financial stability that could enhance earnings forecasts. VeriSign's current share price of US$265.37 is below the analyst consensus price target of US$309.0, indicating a 16.44% discount, which resonates with the potential for value growth should the company's revenue and earnings forecasts materialize as expected. In light of our recent valuation report, it seems possible that VeriSign is trading beyond its estimated value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include VRSN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
22 minutes ago
- Yahoo
CRISPR Therapeutics (CRSP) Sees 47% Price Increase Over Last Quarter
CRISPR Therapeutics recently announced significant developments in its in vivo cardiovascular disease programs, notably CTX310 and CTX320, which may have contributed to the company's 47% share price increase over the last quarter. The company's inclusion in multiple indices further enhances its market presence, potentially impacting investor interest positively. Meanwhile, CRISPR reported a net loss in its Q1 earnings, although revenue increased year-over-year. Despite a volatile market backdrop, characterized by declining major indices due to weak job reports and tariff concerns, CRISPR's advancements in therapeutic programs and strategic index additions contrasted against broader market movements. We've spotted 1 risk for CRISPR Therapeutics you should be aware of. Uncover the next big thing with financially sound penny stocks that balance risk and reward. Over the past year, CRISPR Therapeutics reported a total shareholder return of 9.74%. While the company's shares outperformed the US Biotechs industry, which returned a decline of 8.4% over the same period, it lagged behind the broader US Market's 17.7% return. The favorable performance relative to its industry can be linked to its strategic advancements in cardiovascular disease programs and inclusion in various Russell indices. The recent developments highlighted in the introduction, particularly the positive updates in CRISPR's cardiovascular programs and index additions, could potentially influence expectations around future revenue and earnings. Analysts forecast strong revenue growth of 57.3% annually, despite the company's forecast to remain unprofitable over the next three years. Meanwhile, with the current share price at $56.09, the market seems to discount the consensus analyst price target of $80.91, reflecting a substantial perceived upside potential in the stock. This price movement suggests that investors might see potential growth opportunities, even as the company navigates its profitability challenges. The valuation report we've compiled suggests that CRISPR Therapeutics' current price could be quite moderate. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include CRSP. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
22 minutes ago
- Yahoo
Old Dominion Freight Line (ODFL) Sees 10% Stock Drop Over Last Quarter
Old Dominion Freight Line reported disappointing second-quarter earnings, with sales and net income both declining compared to the previous year. Despite affirmative news about a 7.7% dividend increase and share repurchase activity, ODFL saw its stock fall by 10.23% over the past quarter. This decline mirrored broader market concerns, as stocks generally fell due to weak job reports and renewed tariff worries. Old Dominion's on-market total return decline may have been amplified by these external economic pressures, alongside its own decreased financial performance, reinforcing the downward trend across the transportation sector. Buy, Hold or Sell Old Dominion Freight Line? View our complete analysis and fair value estimate and you decide. AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. The disappointing second-quarter earnings reported by Old Dominion Freight Line have intensified the potential challenges discussed in the company's narrative, especially in terms of revenue growth and margin pressures. With sales and net income both declining compared to the previous year, forecasting a revenue increase of 5.4% annually over three years may prove difficult if economic conditions remain unfavorable and less-than-truckload volumes continue to decrease. The company's efforts to improve operating efficiency and protect its operating ratio are crucial to mitigate the impact of rising overhead costs and maintain net margins. Old Dominion's total shareholder return of 55.86% over the past five years provides a broader context of its performance, showing resilience and solid returns in the long run despite the recent quarterly setback. This compares favorably to its one-year underperformance relative to the US Transportation Industry, which experienced a 7.5% increase, highlighting the impact of current economic challenges on its recent share price behavior. When compared against the analyst price target of $161.82, the current share price of $141.85 suggests a potential undervaluation by market players in the context of long-term growth potential, despite short-term headwinds. Jump into the full analysis health report here for a deeper understanding of Old Dominion Freight Line. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ODFL. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
